These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
308 related articles for article (PubMed ID: 27301674)
1. A new paradigm for predicting risk of Torsades de Pointes during drug development: Commentary on: "Improved prediction of drug-induced Torsades de Pointes through simulations of dynamics and machine learning algorithms". McCauley MD; Darbar D Clin Pharmacol Ther; 2016 Oct; 100(4):324-6. PubMed ID: 27301674 [TBL] [Abstract][Full Text] [Related]
2. Predicting the Unpredictable: Drug-Induced QT Prolongation and Torsades de Pointes. Schwartz PJ; Woosley RL J Am Coll Cardiol; 2016 Apr; 67(13):1639-1650. PubMed ID: 27150690 [TBL] [Abstract][Full Text] [Related]
3. A new biomarker--index of cardiac electrophysiological balance (iCEB)--plays an important role in drug-induced cardiac arrhythmias: beyond QT-prolongation and Torsades de Pointes (TdPs). Lu HR; Yan GX; Gallacher DJ J Pharmacol Toxicol Methods; 2013; 68(2):250-259. PubMed ID: 23337247 [TBL] [Abstract][Full Text] [Related]
4. An explainable algorithm for detecting drug-induced QT-prolongation at risk of torsades de pointes (TdP) regardless of heart rate and T-wave morphology. Alahmadi A; Davies A; Royle J; Goodwin L; Cresswell K; Arain Z; Vigo M; Jay C Comput Biol Med; 2021 Apr; 131():104281. PubMed ID: 33636421 [TBL] [Abstract][Full Text] [Related]
5. Persistent atrial fibrillation is associated with reduced risk of torsades de pointes in patients with drug-induced long QT syndrome. Darbar D; Kimbrough J; Jawaid A; McCray R; Ritchie MD; Roden DM J Am Coll Cardiol; 2008 Feb; 51(8):836-42. PubMed ID: 18294569 [TBL] [Abstract][Full Text] [Related]
6. Epidemiology of symptomatic drug-induced long QT syndrome and Torsade de Pointes in Germany. Sarganas G; Garbe E; Klimpel A; Hering RC; Bronder E; Haverkamp W Europace; 2014 Jan; 16(1):101-8. PubMed ID: 23833046 [TBL] [Abstract][Full Text] [Related]
7. Giant T-U waves precede torsades de pointes in long QT syndrome: a systematic electrocardiographic analysis in patients with acquired and congenital QT prolongation. Kirchhof P; Franz MR; Bardai A; Wilde AM J Am Coll Cardiol; 2009 Jul; 54(2):143-9. PubMed ID: 19573731 [TBL] [Abstract][Full Text] [Related]
8. Fluconazole-associated QT interval prolongation and Torsades de Pointes in a paediatric patient. Ünal Yüksekgönül A; Ertuğrul İ; Karagöz T Cardiol Young; 2021 Dec; 31(12):2035-2037. PubMed ID: 34024302 [TBL] [Abstract][Full Text] [Related]
9. Drug-induced QT prolongation and sudden death. Del Rosario ME; Weachter R; Flaker GC Mo Med; 2010; 107(1):53-8. PubMed ID: 20222297 [TBL] [Abstract][Full Text] [Related]
10. Electrocardiographic predictors of bradycardia-induced torsades de pointes in patients with acquired atrioventricular block. Cho MS; Nam GB; Kim YG; Hwang KW; Kim YR; Choi H; Kim SH; Rhee KS; Kim NJ; Kim JS; Kim J; Choi KJ; Kim YH Heart Rhythm; 2015 Mar; 12(3):498-505. PubMed ID: 25460857 [TBL] [Abstract][Full Text] [Related]
11. Takotsubo cardiomyopathy and QT interval prolongation: who are the patients at risk for torsades de pointes? Samuelov-Kinori L; Kinori M; Kogan Y; Swartzon M; Shalev H; Guy D; Ferenidou F; Mashav N; Sadeh B; Atzmony L; Kliuk-Ben-Basat O; Steinvil A; Justo D J Electrocardiol; 2009; 42(4):353-357.e1. PubMed ID: 19261294 [TBL] [Abstract][Full Text] [Related]
12. Acquired prolongation of QT interval as a risk factor for torsade de pointes ventricular tachycardia: a narrative review for the anesthesiologist and intensivist. Uvelin A; Pejaković J; Mijatović V J Anesth; 2017 Jun; 31(3):413-423. PubMed ID: 28229241 [TBL] [Abstract][Full Text] [Related]
13. Improved Prediction of Drug-Induced Torsades de Pointes Through Simulations of Dynamics and Machine Learning Algorithms. Lancaster MC; Sobie EA Clin Pharmacol Ther; 2016 Oct; 100(4):371-9. PubMed ID: 26950176 [TBL] [Abstract][Full Text] [Related]
15. Adenosine induced torsades de pointes in a child with congenital long QT syndrome. Celiker A; Tokel K; Cil E; Ozkutlu S; Ozme S Pacing Clin Electrophysiol; 1994 Nov; 17(11 Pt 1):1814-7. PubMed ID: 7838793 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of the QT interval in patients with drug-induced QT prolongation and torsades de pointes. Krisai P; Vlachos K; Ramirez FD; Nakatani Y; Nakashima T; Takagi T; Kamakura T; Surget E; André C; Cheniti G; Welte N; Chauvel R; Tixier R; Duchateau J; Pambrun T; Derval N; Hocini M; Jaïs P; Haïssaguerre M; Sacher F J Cardiovasc Electrophysiol; 2020 Oct; 31(10):2696-2701. PubMed ID: 32700358 [TBL] [Abstract][Full Text] [Related]
17. Severe primary hypothyroidism manifesting with torsades de pointes. Schenck JB; Rizvi AA; Lin T Am J Med Sci; 2006 Mar; 331(3):154-6. PubMed ID: 16538077 [TBL] [Abstract][Full Text] [Related]
18. Torsades de pointes and long QT syndromes. Janeira LF Am Fam Physician; 1995 Oct; 52(5):1447-53. PubMed ID: 7572567 [TBL] [Abstract][Full Text] [Related]
19. QT interval prolongation and the risk of torsades de pointes: essentials for clinicians. Trinkley KE; Page RL; Lien H; Yamanouye K; Tisdale JE Curr Med Res Opin; 2013 Dec; 29(12):1719-26. PubMed ID: 24020938 [TBL] [Abstract][Full Text] [Related]